GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » NovMetaPharma Co Ltd (XKRX:229500) » Definitions » FFO

NovMetaPharma Co (XKRX:229500) FFO


View and export this data going back to 2015. Start your Free Trial

What is NovMetaPharma Co FFO?

FFO (Funds from operations) only applies to REITs.


NovMetaPharma Co Business Description

Traded in Other Exchanges
N/A
Address
727 13, Gangnam-gu, Seoul eonju layer, Seoul, KOR
NovMetaPharma Co Ltd researches and develops new medicines and health supplements for metabolic diseases. The company is developing a therapeutic agent that is in Phase 2a clinical trial for Type 2 diabetes and obesity. It also develops therapeutic agents for Alzheimer's disease, immune system diseases, osteoporosis, and non-alcoholic fatty liver diseases.